OncoMatch

OncoMatch/Clinical Trials/NCT04794699

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Is NCT04794699 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including IDE397 and Docetaxel for solid tumor.

Phase 1RecruitingIDEAYA BiosciencesNCT04794699Data as of May 2026

Treatment: IDE397 · Docetaxel · Paclitaxel · Sacituzumab govitecan — This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with other anticancer agents including taxanes (docetaxel, paclitaxel), or sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Biomarker criteria

Required: MTAP deletion

Have evidence of homozygous loss of MTAP or MTAP deletion

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Cannot have received: MAT2A inhibitor

Previous treatment with a MAT2A inhibitor

Cannot have received: PRMT inhibitor

Previous treatment with a PRMT inhibitor

Cannot have received: (sacituzumab govitecan)

Previous treatment with ... sacituzumab govitecan

Lab requirements

Liver function

Adequate organ function; current active liver or biliary disease excluded

Cardiac function

Clinically significant cardiac abnormalities excluded

Adequate organ function; current active liver or biliary disease excluded; Clinically significant cardiac abnormalities excluded

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Honor Health Research Institute · Scottsdale, Arizona
  • Rockefeller Cancer Institute · Little Rock, Arkansas
  • City of Hope · Duarte, California
  • Hoag Memorial Hospital · Newport Beach, California
  • Providence Medical Group · Santa Rosa, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify